| Filed On | Filing |
|---|---|
| 16 Nov 2026 | Form 4 |
| 13 Nov 2026 | Form 4 |
| 13 Nov 2026 |
Form 4: Douglas Richard, Director
Bought 200,000 shares ($129K) |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
8-K: Other Events
On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a re... |
| 06 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease |
| 12 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 30 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
COMMERCIAL LEASE 1 Page PARTIES Bradford Street, LLC, LESSOR, which expression shall include heirs, successors, and assigns where the context so admits, does hereby lease to Aldeyra Therapeutics, Inc., 131 Hartwell Ave, Suite 320, Lexing... |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 15 Jul 2026 |
8-K: Other Events
On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Applica... |
| 11 Jun 2026 |
Form 4: Miller-Rich Nancy, Director
Granted 73,318 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Douglas Richard, Director
Granted 92,232 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Phillips Gary M., Director
Granted 81,613 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Clark William D, Director
Granted 72,323 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Walker Neal, Director
Granted 73,318 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Bronstein Ben, Director
Granted 80,286 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Deptula-hicks Darlene M, Director
Granted 94,313 Stock Option (Right to Buy) |
Loading...